Stocks · News reference
Gilead Sciences maintains an option to license Assembly Biosciences' ABI-6250 for chronic HDV infection following the completion of a Phase 2 clinical study.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Gilead Sciences reported strong third-quarter 2026 financial results, exceeding analyst expectations for both revenue and earnings per share, and raised its full-year base business revenue guidance.
Marvell is reportedly in advanced talks to acquire Lumentum to control AI optics supply, a critical bottleneck in AI infrastructure. Alphabet slumped 10% despite strong cloud growth due to massive capital expenditures and negative free cash flow. Several earnings reports showed mixed results: Fortinet fell 25% on weak guidance, ServiceNow dropped 19% due to AI deployment costs, while Microsoft, Sterling Infrastructure, and Chipotle posted gains. DoorDash may acquire Instacart to compete in grocery delivery dominated by Instacart's 68% market share.
Kymera Therapeutics reported Q3 2026 financial results with positive Phase 1 data for KT-579 (IRF5 degrader) showing deep, sustained target degradation and favorable safety profile. The company is advancing KT-621 (STAT6 degrader) in Phase 2b trials for atopic dermatitis and asthma, with AD topline data expected by year-end 2026. Kymera maintains strong financial position with $1.6 billion in cash providing runway into 2029.